Home › Trials › NCT06864988

Treatment for macular neovascularization caused by age-related macular degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Phase 3 Interventional 4D Molecular Therapeutics · NCT06864988

This study is testing a new treatment called 4D-150 to see if it can help adults with vision problems caused by age-related macular degeneration, compared to a standard treatment.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment400 (estimated)
Ages50 Years and up
SexAll
Sponsor4D Molecular Therapeutics Industry-sponsored
Locations95 sites (Phoenix, Arizona and 94 other locations)
Trial IDNCT06864988 on ClinicalTrials.gov

What this trial studies

This Phase 3 clinical trial evaluates the efficacy of 4D-150, an investigational treatment, in adults suffering from macular neovascularization secondary to age-related macular degeneration (AMD). Participants will be randomly assigned to receive either 4D-150 or EYLEA®, an established treatment, to compare their effects on the condition. The study focuses on treatment-naïve patients with active macular neovascularization, utilizing advanced imaging techniques to confirm eligibility and monitor treatment response. The trial aims to provide insights into the potential benefits of 4D-150 in improving visual outcomes for patients with this condition.

Who should consider this trial

Good fit: Ideal candidates are adults aged 50 and older with treatment-naïve macular neovascularization secondary to AMD.

Not a fit: Patients with macular neovascularization from causes other than AMD or those with certain ocular conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve vision and quality of life for patients with macular neovascularization due to AMD.

How similar studies have performed: Previous studies have shown promising results with similar approaches in treating macular neovascularization, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* ≥50 years of age at time of consent
* Treatment naïve MNV secondary to nAMD in the study eye
* Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT), in the study eye, at the Screening Visit confirmed by the Reading Center
* Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center
* BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit

Exclusion Criteria:

Ocular Conditions:

* MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinal hemorrhage in the foveal central subfield (1 mm diameter))
* History of retinal detachment in the study eye
* History of or presence of active inflammation in either eye
* Glaucoma or intraocular hypertension requiring more than 2 topical medications for control

Systemic Conditions and Considerations:

* Major illness or major surgical procedure in the 28 days prior to the Screening Visit
* Uncontrolled blood pressure
* Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit
* History of autoimmune condition that may predispose to the development of uveitis

Where this trial is running

Phoenix, Arizona and 94 other locations

+45 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Macular Neovascularization Secondary to Age-Related Macular DegenerationAge-related macular degenerationAMDExudative AMDNeovascular AMDExudative age-related macular degenerationNeovascular age-related macular degenerationWet age-related macular degeneration
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.